Key result
Routine pretreatment with a P2Y12 inhibitor in NSTE-ACS patients undergoing early invasive stratification lacks proven ischemic benefit and is associated with increased bleeding risk.
Why the study?
Does pretreatment with a second antiplatelet agent reduce ischemic events in patients with non-ST elevation acute coronary syndrome?
Does pretreatment with a second antiplatelet agent reduce ischemic events in patients with non-ST elevation acute coronary syndrome?
Routine pretreatment with a second antiplatelet agent in NSTE-ACS patients undergoing an early invasive strategy does not improve ischemic outcomes and significantly increases bleeding risk.
Answers are grounded in this paper and cite their sources.
Challenges routine P2Y12 pretreatment in early invasive NSTE-ACS; leaves open optimal timing or agent selection.
Dual antiplatelet therapy is a well-established treatment in patients with non-ST elevation acute coronary syndrome (NSTE-ACS), with class I of recommendation (level of evidence A) in current national and international guidelines. Nonetheless, these guidelines are not precise or consensual regarding the best time to start the second antiplatelet agent. The evidences are conflicting, and after more than a decade using clopidogrel in this scenario, benefits from the routine pretreatment, i.e. without knowing the coronary anatomy, with dual antiplatelet therapy remain uncertain. The recommendation for the upfront treatment with clopidogrel in NSTE-ACS is based on the reduction of non-fatal events in studies that used the conservative strategy with eventual invasive stratification, after many days of the acute event. This approach is different from the current management of these patients, considering the established benefits from the early invasive strategy, especially in moderate to high-risk patients. The only randomized study to date that specifically tested the pretreatment in NSTE-ACS in the context of early invasive strategy, used prasugrel, and it did not show any benefit in reducing ischemic events with pretreatment. On the contrary, its administration increased the risk of bleeding events. This study has brought the pretreatment again into discussion, and led to changes in recent guidelines of the American and European cardiology societies. In this paper, the authors review the main evidence of the pretreatment with dual antiplatelet therapy in NSTE-ACS.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2016) conducted a review in Non-ST elevation acute coronary syndrome (NSTE-ACS). Pretreatment with a second antiplatelet agent (P2Y12 inhibitor) vs. Administration after coronary anatomy is known was evaluated. Routine pretreatment with a P2Y12 inhibitor in NSTE-ACS patients undergoing early invasive stratification lacks proven ischemic benefit and is associated with increased bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: